id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2026-0133-0004,DEA,DEA-2026-0133,DEA-1442 HHS Letter to DEA 06112025,Supporting & Related Material,,2026-01-20T05:00:00Z,2026,1,,,2026-01-20T23:39:08Z,,0,0,09000064b9162339
DEA-2026-0133-0003,DEA,DEA-2026-0133,DEA-1442 DEA Letter to HHS 11012024,Supporting & Related Material,,2026-01-20T05:00:00Z,2026,1,,,2026-02-12T21:01:03Z,,0,1,09000064b9162338
DEA-2026-0133-0002,DEA,DEA-2026-0133,DEA-1442 3-Factor Analysis 2-Fluorodeschloroketamine January 2026,Supporting & Related Material,,2026-01-20T05:00:00Z,2026,1,,,2026-01-20T23:39:02Z,,0,0,09000064b9162337
DEA-2026-0133-0005,DEA,DEA-2026-0133,DEA-1442 HHS Letter to DEA 11082024,Supporting & Related Material,,2026-01-20T05:00:00Z,2026,1,,,2026-01-20T23:39:10Z,,0,0,09000064b916233a
DEA-2026-0133-0006,DEA,DEA-2026-0133,DEA-1442 DEA Letter to HHS 05282025,Supporting & Related Material,,2026-01-20T05:00:00Z,2026,1,,,2026-02-12T21:01:51Z,,0,1,09000064b916233b
DEA-2025-0918-0003,DEA,DEA-2025-0918,251203 OASH to DEA draft letter 4 synthetic cannabinoids 8FA_signed 12032025,Supporting & Related Material,,2025-12-18T05:00:00Z,2025,12,,,2025-12-18T19:22:36Z,,0,0,09000064b90eed87
DEA-2025-0918-0005,DEA,DEA-2025-0918,4F-MDMB-BUTICA ADB-4en-PINACA 5F-EDMB-PICA MMB-FUBICA 8-Factor Analysis December 2025 DEA,Supporting & Related Material,,2025-12-18T05:00:00Z,2025,12,,,2025-12-18T19:22:42Z,,0,0,09000064b90eed89
DEA-2025-0918-0004,DEA,DEA-2025-0918,4F-MDMB-BUTICA ADB-4en-PINACA 5F-EDMB-PICA MMB-FUBICA 8-Factor December 2025 HHS,Supporting & Related Material,,2025-12-18T05:00:00Z,2025,12,,,2025-12-18T19:22:39Z,,0,0,09000064b90eed88
DEA-2025-0885-0003,DEA,DEA-2025-0885,HHS letter to DEA Bromazolam 07102025,Supporting & Related Material,,2025-12-15T05:00:00Z,2025,12,,,2025-12-15T20:47:51Z,,0,0,09000064b90d40f8
DEA-2025-0885-0002,DEA,DEA-2025-0885,HHS letter to DEA Bromazolam 06282024,Supporting & Related Material,,2025-12-15T05:00:00Z,2025,12,,,2025-12-15T20:47:46Z,,0,0,09000064b90d40f6
DEA-2025-0885-0004,DEA,DEA-2025-0885,DEA 3-Factor Analysis Bromazolam December 2025,Supporting & Related Material,,2025-12-15T05:00:00Z,2025,12,,,2025-12-15T20:47:54Z,,0,0,09000064b90d40f7
DEA-2025-0852-0005,DEA,DEA-2025-0852,HHS Letter to DEA cumyl-PEGACLONE_112024,Supporting & Related Material,,2025-12-12T05:00:00Z,2025,12,,,2025-12-13T02:46:04Z,,0,0,09000064b90cb028
DEA-2025-0852-0007,DEA,DEA-2025-0852,HHS Letter to DEA cumyl-PEGACLONE_112024,Supporting & Related Material,,2025-12-12T05:00:00Z,2025,12,,,2025-12-13T02:50:33Z,,0,0,09000064b90cb02a
DEA-2025-0852-0006,DEA,DEA-2025-0852,CUMYL-PEGACLONE HHS 8 Factor Review,Supporting & Related Material,,2025-12-12T05:00:00Z,2025,12,,,2025-12-13T02:50:28Z,,0,0,09000064b90cb029
DEA-2025-0852-0008,DEA,DEA-2025-0852,CUMYL PEGACLONE DEA 8-Factor Analysis_1222025,Supporting & Related Material,,2025-12-12T05:00:00Z,2025,12,,,2025-12-13T02:50:36Z,,0,0,09000064b90cb02b
DEA-2025-0852-0004,DEA,DEA-2025-0852,CUMYL-PEGACLONE HHS 8 Factor Review,Supporting & Related Material,,2025-12-12T05:00:00Z,2025,12,,,2025-12-13T02:46:02Z,,0,0,09000064b90cb027
DEA-2025-0852-0003,DEA,DEA-2025-0852,CUMYL PEGACLONE DEA 8-Factor Analysis_1222025,Supporting & Related Material,,2025-12-12T05:00:00Z,2025,12,,,2025-12-13T02:45:59Z,,0,0,09000064b90cb026
DEA-2025-0588-0002,DEA,DEA-2025-0588,Seven benzimidazole opioids 811h no objection ASH to DEA 22Apr2025.AA,Supporting & Related Material,,2025-10-16T04:00:00Z,2025,10,,,2025-10-17T03:33:17Z,,0,0,09000064b902eca3
DEA-2025-0555-0003,DEA,DEA-2025-0555,8FA MDMB-4en-PINACA,Supporting & Related Material,,2025-10-03T04:00:00Z,2025,10,,,2025-10-03T22:46:34Z,,0,0,09000064b8ff1b92
DEA-2025-0555-0004,DEA,DEA-2025-0555,SIGNED - OASH to DEA Ltr 8FA MDMB-PINACA.VAS,Supporting & Related Material,,2025-10-03T04:00:00Z,2025,10,,,2025-10-03T22:46:38Z,,0,0,09000064b8ff1b94
DEA-2025-0555-0002,DEA,DEA-2025-0555,MDMB-4en-PINACA 8F Oct 2025,Supporting & Related Material,,2025-10-02T04:00:00Z,2025,10,,,2025-10-03T01:16:43Z,,0,0,09000064b8fefe68
DEA-2025-0192-0002,DEA,DEA-2025-0192,DEA-1494 Three Factor Analysis for Temporary Control of Seven Benzimidazole-Opioids,Supporting & Related Material,,2025-08-01T04:00:00Z,2025,8,,,2025-08-02T00:46:00Z,,0,0,09000064b8ecca29
DEA-2022-0145-0008,DEA,DEA-2022-0145,DEA989 HHS 8-Factor Analysis,Supporting & Related Material,,2025-07-25T04:00:00Z,2025,7,,,2025-07-25T21:33:08Z,,0,0,09000064b8ea2f07
DEA-2022-0145-0007,DEA,DEA-2022-0145,DEA989 DEA 8-Factor Analysis,Supporting & Related Material,,2025-07-25T04:00:00Z,2025,7,,,2025-07-25T21:33:05Z,,0,0,09000064b8e9d6f4
DEA-2025-0078-0003,DEA,DEA-2025-0078,DEA Eight Factor 3 FRS_2025,Supporting & Related Material,,2025-06-13T04:00:00Z,2025,6,,,2025-06-13T19:26:14Z,,0,0,09000064b8e081ed
DEA-2025-0078-0002,DEA,DEA-2025-0078,3 FRS 8FA Review,Supporting & Related Material,,2025-06-13T04:00:00Z,2025,6,,,2025-06-13T19:25:56Z,,0,0,09000064b8e081ec
DEA-2025-0081-0004,DEA,DEA-2025-0081,SIGNED - OASH to DEA Ltr 3-MeO PCP.VAS,Supporting & Related Material,,2025-06-10T04:00:00Z,2025,6,,,2025-06-10T17:28:14Z,,0,0,09000064b8ddfd9d
DEA-2025-0081-0002,DEA,DEA-2025-0081,DEA1146 8 Factor 3-MeO-PCP,Supporting & Related Material,,2025-06-10T04:00:00Z,2025,6,,,2025-06-10T17:27:40Z,,0,0,09000064b8ddfd9b
DEA-2025-0081-0003,DEA,DEA-2025-0081,HHS 8FA 3-MeO-PCP Review,Supporting & Related Material,,2025-06-10T04:00:00Z,2025,6,,,2025-06-10T17:27:57Z,,0,0,09000064b8ddfd9c
DEA-2025-0075-0002,DEA,DEA-2025-0075,8FA HHS Report Review 4-Fluoroamphetamine,Supporting & Related Material,,2025-06-03T04:00:00Z,2025,6,,,2025-06-03T21:10:52Z,,0,0,09000064b8dd15a3
DEA-2025-0075-0003,DEA,DEA-2025-0075,FINAL SIGNED - OASH Letter to DEA Ltr 4-Fluroamphetamine,Supporting & Related Material,,2025-06-03T04:00:00Z,2025,6,,,2025-06-03T21:11:11Z,,0,0,09000064b8dd15a4
DEA-2025-0075-0004,DEA,DEA-2025-0075,DEA1180 Background Review 4-Fluoroamphetamine,Supporting & Related Material,,2025-06-03T04:00:00Z,2025,6,,,2025-06-03T21:11:41Z,,0,0,09000064b8dd15a5
DEA-2024-0148-0004,DEA,DEA-2024-0148,7-FRS HHS 8FA Review,Supporting & Related Material,,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T17:10:13Z,,0,0,09000064868970a9
DEA-2024-0148-0003,DEA,DEA-2024-0148,SIGNED OASH to DEA letter 7FRS 8FA_10.25.24,Supporting & Related Material,,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T17:09:46Z,,0,0,09000064868970aa
DEA-2024-0148-0005,DEA,DEA-2024-0148,7-FRS DEA 8 Factor Analysis_2024,Supporting & Related Material,,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T17:10:26Z,,0,0,09000064868970a8
DEA-2024-0144-0003,DEA,DEA-2024-0144,4-CMC HHS 8FA Review,Supporting & Related Material,,2024-12-30T05:00:00Z,2024,12,,,2024-12-30T17:15:04Z,,0,0,0900006486891597
DEA-2024-0144-0004,DEA,DEA-2024-0144,4-CMC DEA 8 Factor Analysis_092024,Supporting & Related Material,,2024-12-30T05:00:00Z,2024,12,,,2024-12-30T17:15:09Z,,0,0,0900006486891598
DEA-2024-0144-0002,DEA,DEA-2024-0144,SIGNED - OASH to DEA Ltr 4-CMC.VAS,Supporting & Related Material,,2024-12-30T05:00:00Z,2024,12,,,2024-12-30T17:15:00Z,,0,0,0900006486891596
DEA-2024-0118-0002,DEA,DEA-2024-0118,DEA-1337 Three Factor Analysis for Temporary Control of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene,Supporting & Related Material,,2024-09-17T04:00:00Z,2024,9,,,2024-09-17T20:07:23Z,,0,0,0900006486732f62
DEA-2024-0059-0007,DEA,DEA-2024-0059,2016-17954-DEA-426,Supporting & Related Material,,2024-05-21T04:00:00Z,2024,5,,,2024-05-21T13:55:44Z,,0,0,090000648657624c
DEA-2024-0059-0006,DEA,DEA-2024-0059,2016-17954-HHS,Supporting & Related Material,,2024-05-21T04:00:00Z,2024,5,,,2024-05-21T13:55:31Z,,0,0,090000648657624b
DEA-2024-0059-0004,DEA,DEA-2024-0059,2024-04-11 - AAG Fonzone - Marijuana Rescheduling,Supporting & Related Material,,2024-05-21T04:00:00Z,2024,5,,,2024-05-21T13:46:37Z,,0,0,0900006486576249
DEA-2024-0059-0005,DEA,DEA-2024-0059,2016-17960-DEA-427,Supporting & Related Material,,2024-05-21T04:00:00Z,2024,5,,,2024-05-21T13:55:07Z,,0,0,090000648657624a
DEA-2023-0168-0004,DEA,DEA-2023-0168,FINAL SIGNED ASH Letter to DEA_DOI-DOC_09.28.2020,Supporting & Related Material,,2023-12-14T05:00:00Z,2023,12,,,2023-12-14T16:35:38Z,,0,0,090000648633a0c2
DEA-2023-0168-0005,DEA,DEA-2023-0168,DEA1156 Eight-Factor Review DOI DOC 102023,Supporting & Related Material,,2023-12-14T05:00:00Z,2023,12,,,2023-12-14T16:35:46Z,,0,0,090000648633a0c3
DEA-2023-0049-0006,DEA,DEA-2023-0049,SIGNED - 6 Cannabinoids 811h no objection ASH to DEA.VAS (003) MDC 03072022,Supporting & Related Material,,2023-12-12T05:00:00Z,2023,12,,,2023-12-12T15:13:43Z,,0,0,0900006486329b0d
DEA-2023-0049-0005,DEA,DEA-2023-0049,6 SCs 3 Factor December 2023,Supporting & Related Material,,2023-12-12T05:00:00Z,2023,12,,,2023-12-12T15:13:34Z,,0,0,09000064863298d2
DEA-2023-0147-0002,DEA,DEA-2023-0147,DEA 1143 Three Factor Analysis for Temporary Control of N-desethyl isotonitazene and N-piperidinyl etonitazene,Supporting & Related Material,,2023-11-06T05:00:00Z,2023,11,,,2023-11-06T19:47:05Z,,0,0,090000648621047f
DEA-2023-0149-0002,DEA,DEA-2023-0149,DEA1258 Zuranolone Eight Factors of Analysis September 2023,Supporting & Related Material,,2023-10-31T04:00:00Z,2023,10,,,2023-10-31T17:39:29Z,,0,0,09000064861a5b33
DEA-2023-0149-0003,DEA,DEA-2023-0149,ASH to DEA Letter and 8FA Zuranolone 12Jul2023,Supporting & Related Material,,2023-10-31T04:00:00Z,2023,10,,,2023-10-31T17:39:40Z,,0,0,09000064861a5b32
DEA-2023-0129-0002,DEA,DEA-2023-0129,Ethylphenidate 8-Factor DOE 23-103,Supporting & Related Material,,2023-09-22T04:00:00Z,2023,9,,,2023-09-22T19:17:09Z,,0,0,0900006485fe8668
DEA-2023-0049-0003,DEA,DEA-2023-0049,SIGNED - 6 Cannabinoids 811h no objection ASH to DEA.VAS (003) MDC 03072022,Supporting & Related Material,,2023-05-11T04:00:00Z,2023,5,,,2023-05-11T12:54:36Z,,0,0,09000064859f43b8
DEA-2023-0058-0002,DEA,DEA-2023-0058,FINAL SIGNED - ASHtoDEA draft letter 9 Fentanyl-Related Substances.VAS,Supporting & Related Material,,2023-04-14T04:00:00Z,2023,4,,,2023-04-14T12:21:41Z,,0,0,09000064859444a7
DEA-2023-0058-0003,DEA,DEA-2023-0058,DEA1036 Nine fentanyls 8-factor 04.06.2023,Supporting & Related Material,,2023-04-14T04:00:00Z,2023,4,,,2023-04-14T12:21:56Z,,0,0,09000064859444a8
DEA-2023-0058-0004,DEA,DEA-2023-0058,8FA Nine Fentanyls,Supporting & Related Material,,2023-04-14T04:00:00Z,2023,4,,,2023-04-14T12:22:09Z,,0,0,09000064859444a9
DEA-2023-0049-0002,DEA,DEA-2023-0049,6 SCs 3 Factor April 2022,Supporting & Related Material,,2023-04-04T04:00:00Z,2023,4,,,2023-04-04T15:48:44Z,,0,0,09000064858c4960
DEA-2022-0068-0005,DEA,DEA-2022-0068,FINAL SIGNED - Fenfluramine Letter and 8FA review 16Apr2021,Supporting & Related Material,,2023-01-03T05:00:00Z,2023,1,,,2023-01-03T13:21:30Z,,0,0,090000648557e6b8
DEA-2022-0068-0004,DEA,DEA-2022-0068,DEA945 Eight Factor Analysis Fenfluramine 012022,Supporting & Related Material,,2023-01-03T05:00:00Z,2023,1,,,2023-01-03T13:21:26Z,,0,0,090000648556a0f0
DEA-2022-0145-0002,DEA,DEA-2022-0145,DEA 3-Factor Analysis Etizolam Flualprazolam Clonazolam Diclazepam Flu...,Supporting & Related Material,,2022-12-23T05:00:00Z,2022,12,,,2022-12-23T12:56:32Z,,0,0,090000648554cfbd
DEA-2022-0145-0003,DEA,DEA-2022-0145,SIGNED - Benzodiazepines 811h no objection ASH to DEA.VAS,Supporting & Related Material,,2022-12-23T05:00:00Z,2022,12,,,2022-12-23T12:56:40Z,,0,0,090000648554cfbe
DEA-2022-0051-0004,DEA,DEA-2022-0051,Ganaxolone eight factor_DEA,Supporting & Related Material,,2022-11-09T05:00:00Z,2022,11,,,2022-11-09T16:41:53Z,,0,0,090000648549e073
DEA-2022-0051-0003,DEA,DEA-2022-0051,Ganaxolone 8FA,Supporting & Related Material,,2022-11-09T05:00:00Z,2022,11,,,2022-11-09T16:41:43Z,,0,0,090000648549e072
DEA-2022-0108-0002,DEA,DEA-2022-0108,Bulk Manufacturer Application - Chattem Chemicals - Correction (2022-24105) - DEA1083,Supporting & Related Material,,2022-11-08T05:00:00Z,2022,11,,,2022-11-08T13:25:42Z,,0,0,0900006485499735
DEA-2022-0026-0003,DEA,DEA-2022-0026,DEA824 DEA 8-factor_DOIandDOC_DOE_082021,Supporting & Related Material,,2022-04-11T04:00:00Z,2022,4,,,2022-04-11T14:27:34Z,,0,0,090000648500b68f
DEA-2022-0026-0002,DEA,DEA-2022-0026,FINAL SIGNED ASH Letter to DEA_DOI-DOC_09.28.2020,Supporting & Related Material,,2022-04-11T04:00:00Z,2022,4,,,2022-04-11T14:27:28Z,,0,0,090000648500b69e
DEA-2022-0025-0003,DEA,DEA-2022-0025,Daridorexant eight factor document DOE,Supporting & Related Material,,2022-04-07T04:00:00Z,2022,4,,,2022-04-07T13:15:47Z,,0,0,0900006484fff9ea
DEA-2022-0025-0002,DEA,DEA-2022-0025,Daridorexant ASHtoDEA 22Dec2021,Supporting & Related Material,,2022-04-07T04:00:00Z,2022,4,,,2022-04-07T13:15:39Z,,0,0,0900006484fff9e9
DEA-2022-0025-0004,DEA,DEA-2022-0025,DCT to DEA daridorexant NDA approval notification,Supporting & Related Material,,2022-04-07T04:00:00Z,2022,4,,,2022-04-07T13:15:53Z,,0,0,0900006484fff7f5
DEA-2022-0001-0002,DEA,DEA-2022-0001,4-OH-DIPT Schedule I_05-17-2012,Supporting & Related Material,,2022-01-14T05:00:00Z,2022,1,,,2022-01-14T18:38:33Z,,0,0,0900006484f21925
DEA-2022-0001-0004,DEA,DEA-2022-0001,5-MeO-DET Schedule I_05-17-2012,Supporting & Related Material,,2022-01-14T05:00:00Z,2022,1,,,2022-01-14T18:38:55Z,,0,0,0900006484f21930
DEA-2022-0001-0006,DEA,DEA-2022-0001,DIPT Schedule I_08-14-2012,Supporting & Related Material,,2022-01-14T05:00:00Z,2022,1,,,2022-01-14T18:39:32Z,,0,0,0900006484f21933
DEA-2022-0001-0003,DEA,DEA-2022-0001,5-MeO-AMT Schedule I_04-03-2012,Supporting & Related Material,,2022-01-14T05:00:00Z,2022,1,,,2022-01-14T18:38:44Z,,0,0,0900006484f21926
DEA-2022-0001-0005,DEA,DEA-2022-0001,Five tryptamines Eight-factor analysis DEA 082021,Supporting & Related Material,,2022-01-14T05:00:00Z,2022,1,,,2022-01-14T18:39:21Z,,0,0,0900006484f21932
DEA-2022-0001-0007,DEA,DEA-2022-0001,5-MeO-MIPT Schedule I_05-17-2012,Supporting & Related Material,,2022-01-14T05:00:00Z,2022,1,,,2022-01-14T18:39:43Z,,0,0,0900006484f21934
DEA-2021-0031-0003,DEA,DEA-2021-0031,Three Factor Analysis for Temporary Control of 7 benzimidazole-opioids,Supporting & Related Material,,2021-12-13T05:00:00Z,2021,12,,,2021-12-13T15:48:07Z,,0,0,0900006484ec1629
DEA-2021-0030-0003,DEA,DEA-2021-0030,DEA568 8 Factor Methoxetamine 092021,Supporting & Related Material,,2021-12-08T05:00:00Z,2021,12,,,2021-12-08T20:11:47Z,,0,0,0900006484eac53f
DEA-2021-0030-0002,DEA,DEA-2021-0030,HHS Scheduling recommendation Methoxetamine,Supporting & Related Material,,2021-12-08T05:00:00Z,2021,12,,,2021-12-08T20:11:38Z,,0,0,0900006484eac53d
DEA-2021-0031-0002,DEA,DEA-2021-0031,Three Factor Analysis for Temporary Control of 7 benzimidazole-opioids 11042021,Supporting & Related Material,,2021-12-08T00:00:00Z,2021,12,,,2021-12-13T15:47:53Z,,0,1,0900006484eac53c
DEA-2021-0025-0003,DEA,DEA-2021-0025,DEA837 8FA 18F  FP-CIT DOE-21-632,Supporting & Related Material,,2021-11-04T04:00:00Z,2021,11,,,2021-11-04T13:48:03Z,,0,0,0900006484e1a226
DEA-2021-0025-0002,DEA,DEA-2021-0025,FINAL SIGNED - Fluoroseek Letter and review 16Apr2021,Supporting & Related Material,,2021-11-04T04:00:00Z,2021,11,,,2021-11-04T13:47:50Z,,0,0,0900006484e1a93b
DEA-2021-0012-0002,DEA,DEA-2021-0012,Mesocarb 8 Factor August 2021,Supporting & Related Material,,2021-08-17T04:00:00Z,2021,8,,,2021-08-17T15:02:59Z,,0,0,0900006484c6c92b
DEA-2021-0012-0003,DEA,DEA-2021-0012,HHS recommendation on Mesocarb Apr 3 2012,Supporting & Related Material,,2021-08-17T04:00:00Z,2021,8,,,2021-08-17T15:05:58Z,,0,0,0900006484c6c92d
DEA-2021-0011-0002,DEA,DEA-2021-0011,Aminpetine 8-factor July 2021,Supporting & Related Material,,2021-07-27T04:00:00Z,2021,7,,,2021-07-27T13:52:16Z,,0,0,0900006484c127b0
DEA-2021-0011-0003,DEA,DEA-2021-0011,Amineptine (DHHS) 12-01-2011,Supporting & Related Material,,2021-07-27T04:00:00Z,2021,7,,,2021-07-27T13:52:23Z,,0,0,0900006484c127b1
DEA-2019-0004-0004,DEA,DEA-2019-0004,DEA_495_8 Factor_Analysis,Supporting & Related Material,,2021-07-16T04:00:00Z,2021,7,,,2021-08-18T13:26:26Z,,0,0,0900006484bfe470
DEA-2019-0004-0005,DEA,DEA-2019-0004,OASH to DEA Letter and 8FA 6 Cathinones SIGNED 7.8.2021,Supporting & Related Material,,2021-07-16T04:00:00Z,2021,7,,,2021-08-18T13:26:40Z,,0,0,0900006484bfe471
DEA-2020-0003-0012,DEA,DEA-2020-0003,Lasmiditan HHS ltr and 8 Factor Analysis 10-23-2019,Supporting & Related Material,,2021-05-25T04:00:00Z,2021,5,,,2021-05-25T16:24:36Z,,0,0,0900006484b34b97
DEA-2020-0003-0011,DEA,DEA-2020-0003,8F Lasmiditan 08062020,Supporting & Related Material,,2021-05-25T04:00:00Z,2021,5,,,2021-05-25T16:16:24Z,,0,0,0900006484b34b5d
DEA-2021-0010-0002,DEA,DEA-2021-0010,Serdexmethylphenidate 8-Factor Analysis DEA 04-2021,Supporting & Related Material,,2021-05-19T04:00:00Z,2021,5,,,2021-05-19T13:04:09Z,,0,0,0900006484b1ad0b
DEA-2021-0010-0003,DEA,DEA-2021-0010,8FA Serdexmethylphenidate 01Mar2021,Supporting & Related Material,,2021-05-19T04:00:00Z,2021,5,,,2021-05-19T13:04:25Z,,0,0,0900006484b1ad0c
DEA-2019-0002-0006,DEA,DEA-2019-0002,HHS Letter 09062018 5F-EDMB-PINACA 5F-MDMB-PICA FUB-AKB48 5F-CUMYL-PINACA FUB-144,Supporting & Related Material,,2021-04-02T04:00:00Z,2021,4,,,2021-04-02T12:38:48Z,,0,0,0900006484a93780
DEA-2019-0002-0007,DEA,DEA-2019-0002,5 SC 8-Factor for permanent control March 2021,Supporting & Related Material,,2021-04-02T04:00:00Z,2021,4,,,2021-04-02T12:40:02Z,,0,0,0900006484a9376a
DEA-2019-0002-0008,DEA,DEA-2019-0002,Final Signed OASH to DEA Letter Five Synthetic Cannabinoids 2.26.21,Supporting & Related Material,,2021-04-02T04:00:00Z,2021,4,,,2021-04-02T12:43:55Z,,0,0,0900006484a93786
DEA-2021-0007-0002,DEA,DEA-2021-0007,FINAL SIGNED - OASH Letter to DEA Four FRS.VAS,Supporting & Related Material,,2021-03-22T04:00:00Z,2021,3,,,2021-03-22T14:52:30Z,,0,0,0900006484a73bef
DEA-2021-0007-0003,DEA,DEA-2021-0007,Four fentanyl related substances DEA 8-Factor,Supporting & Related Material,,2021-03-22T04:00:00Z,2021,3,,,2021-03-22T14:57:00Z,,0,0,0900006484a73c3e
DEA-2021-0006-0003,DEA,DEA-2021-0006,Signed OASH Letter to DEA with Review 02Jul20,Supporting & Related Material,,2021-03-09T05:00:00Z,2021,3,,,2021-03-09T14:01:14Z,,0,0,0900006484a64123
DEA-2021-0006-0002,DEA,DEA-2021-0006,DEA Eight-Factor Analysis for 10 FRS,Supporting & Related Material,,2021-03-09T05:00:00Z,2021,3,,,2021-03-09T14:01:02Z,,0,0,0900006484a64120
DEA-2020-0020-0003,DEA,DEA-2020-0020,5 SCs 8-Factor for permanent control 06302020,Supporting & Related Material,,2021-02-02T05:00:00Z,2021,2,,,2021-02-02T15:27:15Z,,0,0,0900006484a1430f
DEA-2020-0020-0005,DEA,DEA-2020-0020,Five Syn Cannabinoids 8FA Report,Supporting & Related Material,,2021-02-02T05:00:00Z,2021,2,,,2021-02-02T15:27:43Z,,0,0,0900006484a14311
DEA-2020-0020-0004,DEA,DEA-2020-0020,FINAL SIGNED Response Letter to Uttam Dhillon_5.29.2020,Supporting & Related Material,,2021-02-02T05:00:00Z,2021,2,,,2021-02-02T15:27:32Z,,0,0,0900006484a14310